TL;DR: In a randomized study of 50 women with melasma, a regimen of 3% tranexamic acid serum plus moisturizer improved dermatologist-scored periorbital wrinkle scores more than moisturizer alone. The between-group differences were small at week 4 and clearer by weeks 8 and 12. This supports a cautious early fine-line claim for the tested regimen, not a blanket anti-aging claim for every tranexamic acid product.
Bottom line for your skin: Most relevant to early eye-area fine-line appearance. The claim should be tied to the modified Fitzpatrick Wrinkle Scale score and the tested 3% tranexamic acid serum plus moisturizer regimen.
The bars show the size of the reported signal within this post only. They are not meant to compare different measurement scales across studies.
Key Outcomes / Results
| Outcome | Reported result | How to read it |
|---|---|---|
| Week 4 wrinkles | Mean difference -0.12 MFWS points versus moisturizer alone; -0.17 versus -0.05; p=0.007. | Real but small early score difference. |
| Week 8 wrinkles | Mean difference -0.42 MFWS points versus moisturizer alone; -0.44 versus -0.02; p<0.001. | More meaningful separation on the wrinkle scale. |
| Week 12 wrinkles | Mean difference -0.46 MFWS points versus moisturizer alone; -0.43 versus +0.03; p<0.001. | Suggests the benefit persisted after the treatment period. |
| Mechanism | Cell experiments supported effects on senescence, ROS, inflammatory markers, MMPs, and MAPK signaling. | Useful biology, but the human wrinkle score is the customer-relevant endpoint. |
The Study
- Paper: Tranexamic acid protects human dermal fibroblasts from D-galactose-induced senescence via the GPR30/MAPK pathway.
- Journal: Annals of Medicine. Published 2026.
- Human study: 50 women with melasma randomized to 3% tranexamic acid serum plus moisturizer or moisturizer alone.
- Visible endpoint: periorbital wrinkles graded with a modified Fitzpatrick Wrinkle Scale.
- The paper also included fibroblast mechanism experiments.
Dermatologist/Researcher Interpretation
The human result is the part to lead with. The tested tranexamic acid regimen improved eye-area wrinkle scores versus moisturizer alone, especially at weeks 8 and 12.
In mirror terms, this points to softening of early periorbital lines, not dramatic wrinkle reversal. A scale change under half a point can be real and still modest.
The cell work makes the result more biologically plausible, but cells are not faces. The product claim should rest on the human MFWS data, while the fibroblast data stays in the mechanism bucket.
What this means for product claims
Reasonable claim: the tested 3% tranexamic acid serum plus moisturizer improved dermatologist-scored periorbital wrinkle scores versus moisturizer alone in women with melasma. Too far: tranexamic acid reverses aging, rebuilds collagen, or eliminates wrinkles.
Key limitations
- Human study was limited to 50 women with melasma.
- Comparator was moisturizer alone, not another active anti-aging treatment.
- Visible endpoint was periorbital MFWS scoring, not global facial aging, firmness, pores, or elasticity.
- Mechanistic fibroblast findings do not substitute for visible human outcomes.
Reference
Lin Y, Wang Y, Wang W, Deng Z, et al. Tranexamic acid protects human dermal fibroblasts from D-galactose-induced senescence via the GPR30/MAPK pathway. Annals of Medicine. 2026. doi: 10.1080/07853890.2026.2663263. PMID: 42059427.